Nippon Shinyaku announced its results for the first quarter of the fiscal year ending March 2027 (April-June). Consolidated net profit for April-June was ¥10.1 billion, up 22.5% year on year, representing progress of 72.2% against the first-half plan of ¥14.0 billion.
Nippon Shinyaku announced its IFRS-based results at midday on 6 August. Consolidated net profit for the first quarter of the fiscal year ending March 2027 (April-June) was ¥10.1 billion, up 22.5% year on year. Progress against the first-half plan of ¥14.0 billion reached 72.2%.
For the most recent three-month period, the operating margin on sales for April-June fell to 25.1% from 25.5% in the same period a year earlier.
The stocks often compared with Nippon Shinyaku are Eisai, Shionogi Pharmaceutical, Daiichi Sankyo, Chugai Pharmaceutical and Kyowa Kirin. This article was prepared based on publicly disclosed company data.
The article directs readers to future earnings briefing announcements and related materials.